TEV-'192 / Teva - LARVOL DELTA

Evaluation of a Novel PAR2-Targeted Monoclonal Antibody for Skin Inflammatory Conditions (EADV 2024) - "Imiquimod was applied topically once daily for 9 consecutive days on the skin of the back of female hF2RL1 KI Wistar rats to induce skin inflammation and scratching. TEV-56192 is an effective PAR2 antibody that has demonstrated beneficial effects in both ex vivo and in vivo models of skin inflammation and barrier alteration. These findings highlight the therapeutic potential of TEV- 56192 in treating skin indications dominated by skin inflammation and itch sensation."

Dermatitis • Dermatology • Inflammation • Psoriasis • TSLP